Overlap Symptoms of EDS and Osteogenesis Imperfecta May Be New EDS Type, Researchers Contend
Patients with mutations in either the COL1A1 or COL1A2 genes, which provide instructions for making a specific collagen protein, may show symptoms of both Ehlers-Danlos syndrome (EDS) and osteogenesis imperfecta (brittle bone disease), a retrospective study shows. Researchers propose that this overlap is a missing EDS type.
The study ”COL1-related overlap disorder: a novel connective tissue disorder incorporating the osteogenesis imperfecta/Ehlers-Danlos syndrome overlap” was published in the journal Clinical Genetics.
The current 2017 classification defines 13 types of EDS, which are caused by mutations in at least 19 different genes.
The majority of these mutations affect collagen proteins important for the strength, flexibility, and elasticity of connective tissue, which gives glue-like support to body tissues. For example, rare cases of classical EDS can be caused by mutations in the COL1A1 gene, while cardiac-valvular EDS can be caused by mutations in the COL1A2 gene. Both of these genes provide instructions to produce portions of the type 1 collagen protein.
EDS has variable symptoms, which may be similar to other diseases such as osteogenesis imperfecta. EDS is characterized by unusual joint movement range, being able to stretch skin above the normal range, and soft tissue/vascular fragility. Osteogenesis imperfecta is characterized by bone fragility, osteopenia (lower than normal bone mineral density), abnormal tooth development, and hearing loss.
Patients showing mixed features of both EDS and osteogenesis imperfecta previously were considered to have an overlap of both diseases.
Now, researchers at the Fondazione IRCCS‐Casa Sollievo della Sofferenza in Italy have redefined the osteogenesis imperfecta and EDS overlap as a missing EDS type.
Twenty-one patients from 13 families with suspected EDS were included in this retrospective study. Five mutations in the COL1A1 gene, and eight mutations in the COL1A2 were identified. However, these patients were not diagnosed with the types of EDS commonly associated with these mutations, or with osteogenesis imperfecta.
The majority of the patients’ symptoms were EDS-related, which included having an unusual joint movement range, skin signs, soft-tissue injuries, and chronic musculoskeletal pain. The only symptoms shown related to osteogenesis imperfecta were mildly reduced bone mass, occasional fractures, and short height.
Various techniques were used to analyze the structure and properties of collagen in fibroblasts taken from patients.
The analysis indicated that the fibroblasts — connective tissue cells responsible for the production of collagen and the extracellular matrix, which is the mesh-like scaffold surrounding cells — showed properties more typical of EDS than osteogenesis imperfecta.
The researchers believe these “findings indicate the existence of a wider recognizable spectrum associated with COL1A1/COL1A2,” and suggested that the osteogenesis imperfecta/EDS overlap disorder should refer to “individuals who present multiple EDS-typical features with or without signs of mild/moderate OI [osteogenesis imperfecta], and causative variants in COL1A1 and COL1A2, but lacking the clinical and molecular features of the other EDS variants related to these genes.”
They concluded: “In our opinion, this subgroup of EDS patients should be separated from “classical” OI [osteogenesis imperfecta], at least for multisystem management issues, and may be clinically and molecularly distinguishable from the other EDS variants.”